Serum visfatin levels in women with polycystic ovary syndrome

References

• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861.
   PubMed Web of Science ®Google Scholar
• Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–993.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537–1545.
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431–1437.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–430.
   PubMed Web of Science ®Google Scholar
• Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, Lai MM, Lin CC. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metab Clin Exp 2007;56:1216–1220.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71–72.
   PubMed Web of Science ®Google Scholar
• MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007;9:490–497.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006;30:13–17.
   PubMed Web of Science ®Google Scholar
• Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, Bouloumié A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744–747.
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 2003;52:908–915.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S, Gorska M. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007;22:1824–1829.
   PubMed Web of Science ®Google Scholar
• Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911–2916.
   PubMed Web of Science ®Google Scholar
• Kaminska A, Kopczynska E, Bronisz A, Zmudzinska M, Bielinski M, Borkowska A, Tyrakowski T, Junik R. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010;61:169–173.
   PubMed Web of Science ®Google Scholar
• Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578–1581.
   PubMed Web of Science ®Google Scholar
• Ersoy C, Sadikoglu G, Orhan H, Guclu M, Sarandol E, Akgun MD, Ozcakir A, Imamoglu S. Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine 2010;49:275–278.
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165–3170.
   PubMed Web of Science ®Google Scholar
• Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, Han JF, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006;23:967–973.
   PubMed Web of Science ®Google Scholar
• Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007;76:24–29.
   PubMed Web of Science ®Google Scholar
• Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A, Gerou S, Diamanti-Kandarakis E. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008;19:406–412.
   PubMed Web of Science ®Google Scholar
• Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009;25:241–245.
   PubMed Web of Science ®Google Scholar
• Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006;91:5022–5028.
   PubMed Web of Science ®Google Scholar
• Dikmen E, Tarkun I, Cantürk Z, Cetinarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol 2011;27:475–479.
   PubMed Web of Science ®Google Scholar
• Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, Datz C. Retinol-binding protein 4 in polycystic ovary syndrome–association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab 2009;94:1229–1235.
   PubMed Web of Science ®Google Scholar
• Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 2010;93:880–884.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z, Kirazli S, Yarali H. Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online 2010;20:150–155.
   PubMed Web of Science ®Google Scholar
• Tarkun I, Dikmen E, Cetinarslan B, Cantürk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw 2010;21:272–277.
   PubMed Web of Science ®Google Scholar
• Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:536–542.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SH, Im JA, Lee DC. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 2010;67:67–71.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Ozhan H, Kaya Z, Bulur S, Ayhan E, Can G. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008;19:125–131.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 2009;63:56–62.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283–294.
   PubMed Web of Science ®Google Scholar
• Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525–532.
   PubMed Web of Science ®Google Scholar